

Whole Genome/Exome Sequencing and GenomeWide Association Studies

Effective Date: 03/26/2025

Revision Date: 07/01/2024

Review Date: 03/23/2023

Policy Number: HUM-0496-029

Line of Business: Commercial

Medical Coverage Policy

Table of Contents

[Related Medical/Pharmacy Coverage Policies](#)
[Coverage Limitations](#)
[References](#)

[Description](#)
[Coding Information](#)
[Change Summary](#)

Disclaimer

State and federal law, as well as contract language, including definitions and specific inclusions/exclusions, take precedence over clinical policy and must be considered first in determining eligibility for coverage. Coverage may also differ for our Medicare and/or Medicaid members based on any applicable Centers for Medicare & Medicaid Services (CMS) coverage statements including National Coverage Determinations (NCD), Local Medical Review Policies (LMRP) and/or Local Coverage Determinations. Refer to the [CMS website](#). The member's health plan benefits in effect on the date services are rendered must be used. Clinical policy is not intended to pre-empt the judgment of the reviewing medical director or dictate to health care providers how to practice medicine. Health care providers are expected to exercise their medical judgment in rendering appropriate care. Identification of selected brand names of devices, tests and procedures in a medical coverage policy is for reference only and is not an endorsement of any one device, test or procedure over another. Clinical technology is constantly evolving, and we reserve the right to review and update this policy periodically. No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any shape or form or by any means, electronic, mechanical, photocopying or otherwise, without permission from Humana.

Related Medical/Pharmacy Coverage Policies

[Whole Mitochondrial Genome Sequencing and Multigene Panels for Mitochondrial Disorders](#)

Description

Whole genome sequencing (WGS) is a laboratory test utilized to determine the sequence (arrangement) of an individual's entire genome at a single time. WGS allows the identification of mutations in the genome without having to target a gene or chromosome region based upon an individual's personal or family history. WGS may also be referred to as full genome sequencing, complete genome sequencing or entire genome sequencing.

Exome sequencing, also referred to as whole exome sequencing (WES), is an alternative to WGS. It is a laboratory test used to determine the sequence of the protein coding regions of the genome. The exome is the part of the genome that encodes protein, where roughly 85% of variants are known to contribute to diseases in humans. Exome sequencing has been proposed as a diagnostic method to identify these genetic variants in an individual not diagnosed by traditional diagnostic and genetic testing approaches. WES has been proposed as a methodology to analyze **tumor mutational burden (TMB)**, an emerging biomarker that measures the number of mutations (changes) within the deoxyribonucleic acid (DNA) of cancer cells using tumor biopsy tissue. Determining TMB may be helpful for treatment decisions as well as assessing potential eligibility for clinical trials. An example of a WES test that measures TMB is Omics Core.

Another suggested use for WES is for the detection of **minimal residual disease (MRD)** which is a term used for hematologic malignancies and is defined as the small number of cancer cells that remain in the body following treatment. Examples include, but may not be limited to, Invitae PCM Tissue Profiling and MRD Baseline Assay and Invitae PCM MRD Monitoring.

Exome custom panels (also known as exome backbone tests) are customizable, next-generation sequencing (NGS) assays that utilize the whole exome sequencing platform to sequence single genes or multigene panels. Healthcare providers select genes from a menu of genes to include in the request. These tests, depending on the results, may also reflex to (automatically trigger further testing) exome sequencing. Examples include Custom Slice, Custom Slice Xpanded and Slice.

Duo and trio WES involves testing family members in addition to the proband (first affected individual in a family) to facilitate a diagnosis. Duo WES is performed in the proband and one biologically related individual, typically a parent or sibling. Trio WES is performed using samples from the proband and two relatives, typically both parents. The evaluation of the relatives is referred to as comparator analysis.

A **genome-wide association study (GWAS)**, also referred to as genome-wide analysis, is a method to identify genes involved in human disease by comparing the genome of an individual who have a disease or condition to the genome of an individual without the disease or condition. GWAS are performed using microarrays to search the genome for small variations, called single nucleotide polymorphisms (SNPs) that occur more often in an individual with a specific disorder than in those who do not have a disorder.

Optical genome mapping (OGM) is a technology used to enhance the detection and interpretation of WGS by analyzing ultra-high molecular weight DNA molecules that provides a high-resolution genome-wide analysis highlighting copy number and structural anomalies, including balanced translocations. Examples of OGM testing include, but may not be limited to:

- Augusta Hematology Optical Genome Mapping
- Augusta Optical Genome Mapping
- Chromosome Genome Mapping
- DH Optical Genome Mapping/Digital Karyotyping Assay
- Praxis Optical Genome Mapping
- Praxis Somatic Optical Genome Mapping

OGM may be offered in combination with WGS. Examples include, but may not be limited to:

- Praxis Combined Whole Genome Sequencing and Optical Genome Mapping
- Praxis Somatic Combined Whole Genome Sequencing and Optical Genome Mapping

WGS/WES reanalysis or reevaluation involves taking the raw data generated from a previous WGS/WES study and reprocessing it using updated software and new reference genome versions. Reanalysis or reevaluation differs from retesting.

Transcriptome sequencing is a method of analyzing the complete set of RNA molecules, or transcripts, produced by a cell or tissue at a specific time. Praxis Somatic Transcriptome and Praxis Transcriptome are examples of this type of testing.

Coverage Limitations

Any state mandates for WGS, WES or GWAS take precedence over this medical coverage policy.

Humana members may **NOT** be eligible under the Plan for **WGS, WES or GWAS** for any indication or test including, but may not be limited to:

- Carrier status or reproductive risk including, but may not be limited to:
 - Insight Genome
 - Repro Xpanded Test (individual or couple)
- Combined WES and mitochondrial genome testing including, but may not be limited to:
 - Comparator (parent, sibling) for rare disease (constitutional/heritable disorders) (eg, Genomic Unity Exome Plus Analysis – Comparator [0215U])
 - Proband (first affected individual in a family) for rare disease (constitutional/ heritable disorders) (eg, Genomic Unity Exome Plus Analysis – Proband [0214U])
 - XomeDx Plus Test
- Combined WGS and mitochondrial genomic testing including, but may not be limited to:
 - Comparator (parent, sibling) for rare disease (constitutional/heritable disorders) (eg, Genomic Unity Whole Genome Analysis – Comparator [0213U])
 - Proband (first affected individual in a family) for rare disease (constitutional/heritable disorders) (eg, Genomic Unity Whole Genome Analysis – Proband [0212U])

- Combined WGS and OGM including, but may not be limited to:
 - Praxis Combined Whole Genome Sequencing and Optical Genome Mapping (0267U)
 - Praxis Somatic Combined Whole Genome Sequencing and Optical Genome Mapping (0300U)
- Custom exome panels of single or targeted genes (eg, Custom Slice, Custom SliceXpanded, Slice)
- Duo and Trio WGS or WES including, but may not be limited to:
 - XomeDx – Duo
 - XomeDx – Trio
- Evaluation of any of the following:
 - Alzheimer disease/dementia
 - Ataxia
 - Autism spectrum disorder
 - Congenital anomalies
 - Developmental delay/intellectual disability
 - Dystonia
 - Epilepsy
 - Hearing loss
 - Primary immunodeficiency
 - Psychiatric conditions
 - Stillbirth/fetal demise
- Fetal evaluation including, but may not be limited to, XomeDx Fetal, IriSight CNV Analysis (0469U)
- MRD assessment (baseline or monitoring) by WGS or WES including, but may not be limited to:
 - Invitae PCM Tissue Profiling & MRD Baseline Assay (0306U)
 - Invitae PCM MRD Monitoring (0307U)
 - Precise MRD
- OGM including, but may not be limited to:
 - Augusta Hematology Optical Genome Mapping (0331U)
 - Augusta Optical Genome Mapping (0260U)
 - Chromosome Genome Mapping (0454U)
 - DH Optical Genome Mapping/Digital Karyotyping Assay (0413U)
 - Praxis Optical Genome Mapping (0264U)
 - Praxis Somatic Optical Genome Mapping (0299U)
- Preimplantation genetic testing
- Prenatal screening or diagnosis by WGS or WES including, but may not be limited to:
 - ExomeNext Prenatal

- IriSight Prenatal Analysis (comparator [0336U] or proband [0335U]) ○ XomeDx Prenatal Test (comprehensive or targeted)
- Rapid or ultrarapid WGS or WES including, but may not be limited to:
 - Custom SliceXpanded Priority ○ Custom SliceXanded Xpress Test ○ GenomeXpress Test ○ NICUXpress Panel
 - RCIGM Rapid Whole Genome Sequencing [0094U])
 - RCIGM Rapid Whole Genome Sequencing, Comparator Genome (0425U) ○ RCIGM Ultra-Rapid Whole Genome Sequencing (0426U) ○ XomeDx Priority Test
 - XomeDxXpress Test
- Reanalysis or reevaluation by WGS or WES including, but may not be limited to:
 - Xome Reanalysis Test
 - Xome Subsequent Reanalysis Test
- Somatic WGS or WES including, but may not be limited to:
 - EXaCT-1 Whole Exome Testing [0036U]) ○ Praxis Somatic Whole Genome Sequencing (0297U) ○ Tempus xE
- Targeted gene rearrangement detection by WGS NGS for any of the following:
 - Germline congenital disorders (eg, MatePair Targeted Rearrangements, Congenital [0012U])
 - Hematology (acute myelogenous leukemia [AML]) (eg, MatePair Acute Myeloid Leukemia Panel [0056U])
 - Hematology (hematolymphoid neoplasia) (eg, MatePair Targeted Rearrangements, Hematologic [0014U])
 - Oncology (solid organ neoplasia) (eg, MatePair Targeted Rearrangements, Oncology [0013U])
- TMB assessment by WGS or WES including, but may not be limited to, Omics Core whole exome tumornormal in vitro diagnostic
- Transcriptome including, but may not be limited to:
 - Praxis Somatic Transcriptome (0298U) ○ Praxis Transcriptome (0266U)
- WGS including, but may not be limited to, Praxis Whole Genome Sequencing (0265U)

These are considered experimental/investigational as they are not identified as widely used and generally accepted for the proposed uses as reported in nationally recognized peer-reviewed medical literature published in the English language.

Coding Information

Any codes listed on this policy are for informational purposes only. Do not rely on the accuracy and inclusion of specific codes. Inclusion of a code does not guarantee coverage and/or reimbursement for a service or procedure.

CPT® Code(s)	Description	Comments
81415	Exome (eg, unexplained constitutional or heritable disorder or syndrome); sequence analysis	Not Covered
81416	Exome (eg, unexplained constitutional or heritable disorder or syndrome); sequence analysis, each comparator exome (eg, parents, siblings) (List separately in addition to code for primary procedure)	Not Covered
81417	Exome (eg, unexplained constitutional or heritable disorder or syndrome); re-evaluation of previously obtained exome sequence (eg, updated knowledge or unrelated condition/syndrome)	Not Covered
81425	Genome (eg, unexplained constitutional or heritable disorder or syndrome); sequence analysis	Not Covered
81426	Genome (eg, unexplained constitutional or heritable disorder or syndrome); sequence analysis, each comparator genome (eg, parents, siblings) (List separately in addition to code for primary procedure)	Not Covered
81427	Genome (eg, unexplained constitutional or heritable disorder or syndrome); re-evaluation of previously obtained genome sequence (eg, updated knowledge or unrelated condition/syndrome)	Not Covered
81479	Unlisted molecular pathology procedure	Not Covered if used to report any test outlined in Coverage Limitations section
0036U	Exome (ie, somatic mutations), paired formalin-fixed paraffinembedded tumor tissue and normal specimen, sequence analyses	Not Covered

0094U	Genome (eg, unexplained constitutional or heritable disorder or syndrome), rapid sequence analysis	Not Covered
0212U	Rare diseases (constitutional/heritable disorders), whole genome and mitochondrial DNA sequence analysis, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants, proband	Not Covered
0213U	Rare diseases (constitutional/heritable disorders), whole genome and mitochondrial DNA sequence analysis, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants, each comparator genome (eg, parent, sibling)	Not Covered
0214U	Rare diseases (constitutional/heritable disorders), whole exome and mitochondrial DNA sequence analysis, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants, proband	Not Covered
0215U	Rare diseases (constitutional/heritable disorders), whole exome and mitochondrial DNA sequence analysis, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants, each comparator exome (eg, parent, sibling)	Not Covered
0260U	Rare diseases (constitutional/heritable disorders), identification of copy number variations, inversions, insertions, translocations, and other structural variants by optical genome mapping	Not Covered
0264U	Rare diseases (constitutional/heritable disorders), identification of copy number variations, inversions, insertions, translocations, and other structural variants by optical genome mapping	Not Covered

0265U	Rare constitutional and other heritable disorders, whole genome and mitochondrial DNA sequence analysis, blood, frozen and formalin-fixed paraffin-embedded (FFPE) tissue, saliva, buccal swabs or cell lines, identification of single nucleotide and copy number variants	Not Covered
-------	---	--------------------

0266U	Unexplained constitutional or other heritable disorders or syndromes, tissue-specific gene expression by whole transcriptome and next-generation sequencing, blood, formalin-fixed paraffin-embedded (FFPE) tissue or fresh frozen tissue, reported as presence or absence of splicing or expression changes	Not Covered
0267U	Rare constitutional and other heritable disorders, identification of copy number variations, inversions, insertions, translocations, and other structural variants by optical genome mapping and whole genome sequencing	Not Covered
0297U	Oncology (pan tumor), whole genome sequencing of paired malignant and normal DNA specimens, fresh or formalin-fixed paraffin-embedded (FFPE) tissue, blood or bone marrow, comparative sequence analyses and variant identification	Not Covered
0298U	Oncology (pan tumor), whole transcriptome sequencing of paired malignant and normal RNA specimens, fresh or formalin-fixed paraffin-embedded (FFPE) tissue, blood or bone marrow, comparative sequence analyses and expression level and chimeric transcript identification	Not Covered
0299U	Oncology (pan tumor), whole genome optical genome mapping of paired malignant and normal DNA specimens, fresh frozen tissue, blood, or bone marrow, comparative structural variant identification	Not Covered
0300U	Oncology (pan tumor), whole genome sequencing and optical genome mapping of paired malignant and normal DNA specimens, fresh tissue, blood, or bone marrow, comparative sequence analyses and variant identification	Not Covered
0306U	Oncology (minimal residual disease [MRD]), next-generation targeted sequencing analysis, cell-free DNA, initial (baseline) assessment to determine a patient specific panel for future comparisons to evaluate for MRD	Not Covered

0307U	Oncology (minimal residual disease [MRD]), next-generation targeted sequencing analysis of a patient-specific panel, cellfree DNA, subsequent assessment with comparison to previously analyzed patient specimens to evaluate for MRD	Not Covered
0331U	Oncology (hematolymphoid neoplasia), optical genome mapping for copy number alterations and gene rearrangements utilizing DNA from blood or bone marrow, report of clinically significant alterations	Not Covered

0335U	Rare diseases (constitutional/heritable disorders), whole genome sequence analysis, including small sequence changes, copy number variants, deletions, duplications, mobile element insertions, uniparental disomy (UPD), inversions, aneuploidy, mitochondrial genome sequence analysis with heteroplasmy and large deletions, short tandem repeat (STR) gene expansions, fetal sample, identification and categorization of genetic variants u(Do not report 0335U in conjunction with 81425, 0212U)t	Not Covered
0336U	Rare diseases (constitutional/heritable disorders), whole genome sequence analysis, including small sequence changes, copy number variants, deletions, duplications, mobile element insertions, uniparental disomy (UPD), inversions, aneuploidy, mitochondrial genome sequence analysis with heteroplasmy and large deletions, short tandem repeat (STR) gene expansions, blood or saliva, identification and categorization of genetic variants, each comparator genome (eg, parent) u(Do not report 0336U in conjunction with 81426, 0213U)t	Not Covered
0413U	Oncology (hematolymphoid neoplasm), optical genome mapping for copy number alterations, aneuploidy, and balanced/complex structural rearrangements, DNA from blood or bone marrow, report of clinically significant alterations	Not Covered New Code Effective 10/01/2023
0425U	Genome (eg, unexplained constitutional or heritable disorder or syndrome), rapid sequence analysis, each comparator genome (eg, parents, siblings)	Not Covered New Code Effective 01/01/2024

0426U	Genome (eg, unexplained constitutional or heritable disorder or syndrome), ultra-rapid sequence analysis	Not Covered New Code Effective 01/01/2024
0454U	Rare diseases (constitutional/heritable disorders), identification of copy number variations, inversions, insertions, translocations, and other structural variants by optical genome mapping	Not Covered New Code Effective 07/01/2024
0469U	Rare diseases (constitutional/heritable disorders), whole genome sequence analysis for chromosomal abnormalities, copy number variants, duplications/deletions, inversions, unbalanced translocations, regions of homozygosity (ROH), inheritance pattern that indicate uniparental disomy (UPD), and aneuploidy, fetal sample (amniotic fluid, chorionic villus sample, or products of conception), identification and categorization of	Not Covered New Code Effective 07/01/2024

Page:

	genetic variants, diagnostic report of fetal results based on phenotype with maternal sample and paternal sample, if performed, as comparators and/or maternal cell contamination	
CPT® Category III Code(s)	Description	Comments
No code(s) identified		
HCPCS Code(s)	Description	Comments
No code(s) identified		

References

1. Al-Kouatly HB, Makhamre MM, Rice SM, et al. High diagnosis rate for nonimmune hydrops fetalis with prenatal clinical exome from the Hydrops-Yielding Diagnostic Results of Prenatal Sequencing (HYDROPS) Study. *Genet Med*. 2021;23(7):1325-1333.
2. American Academy of Allergy, Asthma, and Immunology (AAAAI). Practice parameter for the diagnosis and management of primary immunodeficiency. <https://www.aaaai.org>. Published September 12, 2015.
3. American Academy of Child and Adolescent Psychiatry (AACAP). AACAP Official Action. Practice parameter for the assessment and treatment of psychiatric disorders in children and adolescents with intellectual disability (intellectual developmental disorder). <https://www.aacap.org>. Published April 2020.
4. American Academy of Neurology (AAN). Model Coverage Policy. Chromosomal microarray analysis for intellectual disabilities. <https://www.aan.com>. Published August 2013.
5. American Academy of Neurology (AAN). Special Article. Evidence-based guideline summary: diagnosis and treatment of limb-girdle and distal dystrophies. <https://www.aan.com>. Published October 13, 2014.
6. American Academy of Neurology (AAN). Special Article. Evidence-based guideline summary: evaluation, diagnosis and management of congenital muscular dystrophy. <https://www.aan.com>. Published March 30, 2015.

7. American Academy of Ophthalmology (AAO). Clinical Statement. Guidelines on clinical assessment of patients with inherited retinal degenerations. <https://www.aao.org>. Published October 2022.
8. American Academy of Ophthalmology (AAO). Recommendations for genetic testing of inherited eye diseases – 2014. <https://www.aao.org>. Published February 2014.

Whole Genome/Exome Sequencing and Genome-Wide Association Studies

Page: 11 of 19

9. American Academy of Pediatrics (AAP). Clinical Report. Comprehensive evaluation of the child with intellectual disability or global developmental delays. <https://www.aap.org>. Published September 2014. Updated October 2019.
10. American Academy of Pediatrics (AAP). Clinical Report. Identification, evaluation, and management of children with autism spectrum disorder. <https://www.aap.org>. Published January 2020.
11. American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM). Position Statement. The utility of genetic testing in neuromuscular disease: a consensus from the AANEM on the clinical usefulness of genetic testing in the diagnosis of neuromuscular disease. <https://www.aanem.org>. Published April 2016.
12. American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM). Practice Guideline. Evidence-based guideline: diagnosis and treatment of limb-girdle and distal dystrophies. <https://www.aanem.org>. Published October 2014.
13. American College of Medical Genetics and Genomics (ACMG). ACMG Policy Statement. Points to consider in the clinical application of genomic sequencing. <https://www.acmg.net>. Published 2012.
14. American College of Medical Genetics and Genomics (ACMG). ACMG Practice Guideline. Exome and genome sequencing for pediatric patients with congenital anomalies or intellectual disability: an evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG). <https://www.acmg.net>. Published 2021.
15. American College of Medical Genetics and Genomics (ACMG). ACMG Practice Resource. Genetic evaluation of cardiomyopathy: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). <https://www.acmg.net>. Published 2018.
16. American College of Medical Genetics and Genomics (ACMG). Clinical evaluation and etiologic diagnosis of hearing loss: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). <https://www.acmg.net>. Published 2022.

17. American College of Medical Genetics and Genomics (ACMG). ACMG Statement. Points to consider in the reevaluation and reanalysis of genomic test results: a statement of the American College of Medical Genetics and Genomics (ACMG). <https://www.acmg.net>. Published 2019.
18. American College of Medical Genetics and Genomics (ACMG). ACMG Statement. Points to consider when assessing relationships (or suspecting misattributed relationships) during family-based clinical genomic testing: a statement of the American College of Medical Genetics and Genomics (ACMG). <https://www.acmg.net>. Published 2020.
19. American College of Medical Genetics and Genomics (ACMG). ACMG Statement. The use of fetal exome sequencing in prenatal diagnosis: a points to consider document of the American College of Medical Genetics and Genomics. <https://www.acmg.net>. Published 2020.

Whole Genome/Exome Sequencing and Genome-Wide Association Studies

Page: 12 of 19

20. American College of Medical Genetics and Genomics (ACMG). ACMG Systematic Evidence Review. Systematic evidence-based review: outcomes from exome and genome sequencing for pediatric patients with congenital anomalies or intellectual disability. <https://www.acmg.net>. Published 2020.
21. American College of Medical Genetics and Genomics (ACMG). ACMG Technical Standard. Nextgeneration sequencing for constitutional variants in the clinical laboratory, 2021 revision: a technical standard of the American College of Medical Genetics and Genomics (ACMG). <https://www.acmg.net>. Published 2021.
22. American College of Medical Genetics and Genomics (ACMG). Addendum. Focused revision: ACMG practice resource: genetic evaluation of short stature. <https://www.acmg.net>. Updated 2021.
23. American College of Obstetricians and Gynecologists (ACOG). Committee Opinion. Microarrays and next-generation sequencing technology: the use of advanced genetic diagnostic tools in obstetrics and gynecology. <https://www.acog.org>. Published 2013. Updated 2023.
24. American College of Obstetricians and Gynecologists (ACOG). Obstetric Care Consensus. Management of stillbirth. <https://www.acog.org>. Published March 2009. Updated 2021.
25. Bruno LP, Doddato G, Valentino F, et al. New candidates for autism/ intellectual disability identified by whole-exome sequencing. *Int J Mol Sci.* 2021;22(24):13439.

26. ClinicalKey. Clinical Overview. Charcot-Marie-Tooth disease. <https://www.clinicalkey.com>. Published April 26, 2022.
27. ClinicalKey. Clinical Overview. Epilepsy in children. <https://www.clinicalkey.com>. Published April 11, 2022.
28. ClinicalKey. Clinical Overview. Primary immunodeficiency disease. <https://www.clinicalkey.com>. Published January 1, 2023.
29. ClinicalKey. Clinical Overview. Spinocerebellar ataxia. <https://www.clinicalkey.com>. Published January 1, 2023.
30. ClinicalKey. Franklin WA, Aisner DL, Davies KD, et al. Pathology, biomarkers, and molecular diagnostics. *Abeloff's Clinical Oncology*. 6th ed. 2020;15:225-253.e8. <https://www.clinicalkey.com>.
31. Dewey FE, Grove ME, Pan C, et al. Clinical interpretation and implications of whole-genome sequencing. *JAMA*. 2014;311(10):1035-1045.
32. Dimmock DP, Clark MM, Gaughran M, et al. An RCT of rapid genomic sequencing among seriously ill infants results in high clinical utility, changes in management, and low perceived harm. *Am J Hum Genet*. 2020;107(5):942-952.

Whole Genome/Exome Sequencing and Genome-Wide Association Studies

Page: 13 of 19

33. Dong Z, Zhao X, Li Q, et al. Development of coupling controlled polymerizations by adapter-ligation in mate-pair sequencing for detection of various genomic variants in one single assay. *DNA Res*. 2019;6(4):313-325.
34. Drucker TM, Johnson SH, Murphy SJ, Cradic KW, Therneau TM, Vasmatzis G. BIMA V3: an aligner customized for mate pair library sequencing. *Bioinformatics*. 2014;30(11):1627-1629.
35. ECRI Institute. ECRIgene. Insight Genome (HudsonAlpha; Smith Family Clinic) for confirming diagnosis, assessing risk and determining carrier status related to multiple genetic conditions. <https://www.ecri.org>. Published February 2020.

36. ECRI Institute. ECRIgene. TruGenome Undiagnosed Disease (Illumina, Inc.) for confirming diagnosis of single-gene disorders. <https://www.ecri.org>. Published February 2020.
37. ECRI Institute. ECRI Genetic Test Assessment. EXaCT-1 (Weill Cornell Medicine Englander Institute for Precision Medicine) genomic profiling and whole exome sequencing test for guiding targeted cancer therapy. <https://www.ecri.org>. Published June 2021.
38. ECRI Institute. ECRIgene Genetic Test Assessment. Tempus xE (Tempus) to guide targeted therapy for solid tumor cancers. <https://www.ecri.org>. Published October 2020.
39. Farwell KD, Shahmirzadi L, El-Khechen D, et al. Enhanced utility of family-centered diagnostic exome sequencing with inheritance model-based analysis: results from 500 unselected families with undiagnosed genetic conditions. *Genet Med*. 2015;17(7):578-586.
40. Grassi T, Harris FR, Smadbeck JB, et al. Personalized tumor-specific DNA junctions to detect circulating tumor in patients with endometrial cancer. *PLoS One*. 2021;16(6):e0252390.
41. Hayes, Inc. Clinical Utility Evaluation. Clinical utility of whole genome sequencing (WGS) and whole exome sequencing (WES) in patients with intellectual disability (ID). <https://evidence.hayesinc.com>. Published January 21, 2021. Updated February 6, 2022.
42. Hayes, Inc. Clinical Utility Evaluation. Prenatal whole genome sequencing and prenatal whole exome sequencing. <https://evidence.hayesinc.com>. Published June 15, 2020. Updated June 7, 2022.
43. Hayes, Inc. Clinical Utility Evaluation. Whole exome/genome sequencing for neuromuscular disease and movement disorders in adults. <https://evidence.hayesinc.com>. Published March 9, 2022.
44. Hayes, Inc. Clinical Utility Evaluation. Whole exome/genome sequencing for previously undiagnosed pediatric neurodevelopmental disorders. <https://evidence.hayesinc.com>. Published November 12, 2021. Updated October 25, 2022.
45. Hayes, Inc. Clinical Utility Evaluation (ARCHIVED). Whole genome sequencing (WGS) in neonatal and pediatric patients. <https://evidence.hayesinc.com>. Published September 22, 2016. Updated August 12, 2019.

Whole Genome/Exome Sequencing and Genome-Wide Association Studies

Page: 14 of 19

46. Hayes, Inc. Genetic Test Evaluation (GTE) Report (ARCHIVED). Whole exome sequencing for cancer indications. <https://evidence.hayesinc.com>. Published January 20, 2013. Updated July 1, 2014.

47. Hayes, Inc. Genetic Test Evaluation (GTE) Report (ARCHIVED). Whole exome sequencing for noncancer indications. <https://evidence.hayesinc.com>. Published August 13, 2013. Updated August 12, 2014.
48. Ilinca A, Samuelsson S, Piccinelli P, Soller M, Kristoffersson U, Lindgren AG. A stroke gene panel for whole-exome sequencing. *Eur J Hum Genet*. 2019;27(2):317-324.
49. Jamal SM, Yu JH, Chong JX, et al. Practices and policies of clinical exome sequencing providers: analysis and implications. *Am J Med Genet A*. 2013;161A(5):935-950.
50. Kingsmore SF, Cakici JA, Clark MM, et al. A randomized, controlled trial of the analytic and diagnostic performance of singleton and trio, rapid genome and exome sequencing in ill infants. *Am J Hum Genet*. 2019;105(4):719-733.
51. Kingsmore SF, Cole FS. The role of genome sequencing in neonatal intensive care units. *Annu Rev Genomics Hum Genet*. 2022;23:427-448.
52. Lee H, Deignan JL, Dorrani N, et al. Clinical exome sequencing for genetic identification of rare Mendelian disorders. *JAMA*. 2014;312(18):1880-1887.
53. Lord J, McMullan DJ, Eberhardt RY, et al. Prenatal exome sequencing analysis in fetal structural anomalies detected by ultrasonography (PAGE): a cohort study. *Lancet*. 2019;393(10173):747-757.
54. Lunke S, Eggers S, Wilson M, et al. Feasibility of ultra-rapid exome sequencing in critically ill infants and children with suspected monogenic conditions in the Australian Public Health Care System. *JAMA*. 2020;323(24):2503-2511.
55. MCG Health. Whole genome/exome sequencing – autism spectrum disorders. 26th edition. <https://humana.access.mcg.com/index>.
56. MCG Health. Whole genome/exome sequencing – cancer. 26th edition. <https://humana.access.mcg.com/index>.
57. MCG Health. Whole genome/exome sequencing – cardiovascular disorders. 26th edition. <https://humana.access.mcg.com/index>.
58. MCG Health. Whole genome/exome sequencing – congenital anomalies. 26th edition. <https://humana.access.mcg.com/index>.

59. MCG Health. Whole genome/exome sequencing – developmental delay and intellectual disability. 26th edition. <https://humana.access.mcg.com/index>.

Whole Genome/Exome Sequencing and Genome-Wide Association Studies

Page: 15 of 19

60. MCG Health. Whole genome/exome sequencing – metabolic, mitochondrial, and neurologic disorders. 26th edition. <https://humana.access.mcg.com/index>.
61. MCG Health. Whole genome/exome sequencing – primary immunodeficiency disorders. 26th edition. <https://humana.access.mcg.com/index>.
62. National Center for Biotechnology Information (NCBI). Genetic Testing Registry. Charcot-Marie-Tooth hereditary neuropathy overview. <https://www.ncbi.nlm.nih.gov/gtr>. Published September 28, 1998. Updated September 29, 2022.
63. National Center for Biotechnology Information (NCBI). Genetic Testing Registry. Dystrophinopathies. <https://www.ncbi.nlm.nih.gov/gtr>. Published September 5, 2000. Updated January 20, 2022.
64. National Center for Biotechnology Information (NCBI). Genetic Testing Registry. Emery-Dreifuss muscular dystrophy. <https://www.ncbi.nlm.nih.gov/gtr>. Published September 29, 2004. Updated August 25, 2019.
65. National Center for Biotechnology Information (NCBI). Genetic Testing Registry. Hereditary ataxia overview. <https://www.ncbi.nlm.nih.gov/gtr>. Published October 28, 1998. Updated June 16, 2022.
66. National Center for Biotechnology Information (NCBI). Genetic Testing Registry. Hereditary dystonia overview. <https://www.ncbi.nlm.nih.gov/gtr>. Published October 28, 2003. Updated June 22, 2017.
67. National Center for Biotechnology Information (NCBI). Genetic Testing Registry. Hereditary hearing loss and deafness overview. <https://www.ncbi.nlm.nih.gov/gtr>. Published February 14, 1999. Updated July 27, 2017.
68. National Center for Biotechnology Information (NCBI). Genetic Testing Registry. Huntington disease. <https://www.ncbi.nlm.nih.gov/gtr>. Published October 3, 1998. Updated June 11, 2020.
69. National Center for Biotechnology Information (NCBI). Genetic Testing Registry. Neurofibromatosis 1. <https://www.ncbi.nlm.nih.gov/gtr>. Published October 2, 1998. Updated April 21, 2022.

70. National Center for Biotechnology Information (NCBI). Genetic Testing Registry. Neurofibromatosis 2. <https://www.ncbi.nlm.nih.gov/gtr>. Published October 14, 1998. Updated March 15, 2018.
71. National Center for Biotechnology Information (NCBI). Genetic Testing Registry. Parkinson disease overview. <https://www.ncbi.nlm.nih.gov/gtr>. Published May 25, 2004. Updated July 25, 2019.
72. National Center for Biotechnology Information (NCBI). Genetic Testing Registry. X-linked adrenoleukodystrophy. <https://www.ncbi.nlm.nih.gov/gtr>. Published March 26, 1999. Updated February 15, 2018.
73. National Society of Genetic Counselors (NSGC). Practice Guideline. Genetic testing and counseling for the unexplained epilepsies: an evidence-based practice guideline of the National Society of Genetic Counselors. <https://www.nccn.org>. Published October 24, 2022.

Whole Genome/Exome Sequencing and Genome-Wide Association Studies

Page: 16 of 19

74. National Society of Genetic Counselors (NSGC). Practice Resource. Genetic counseling for congenital heart disease – practice resource of the National Society of Genetic Counselors. <https://www.nccn.org>. Published 2022.
75. Palmer EE, Schofield D, Shrestha R, et al. Integrating exome sequencing into a diagnostic pathway for epileptic encephalopathy: evidence of clinical utility and cost effectiveness. *Mol Genet Genomic Med*. 2018;6(2):186-199.
76. Rennert H, Eng K, Zhang T, et al. Development and validation of a whole-exome sequencing test for simultaneous detection of point mutations, indels and copy-number alterations for precision cancer care. *NPJ Genom Med*. 2016;1: 16019.
77. Retterer K, Juusola J, Cho MT, et al. Clinical application of whole-exome sequencing across clinical indications. *Genet Med*. 2016;18(7):696-704.
78. Retterer K, Scuffins J, Schmidt D, et al. Assessing copy number from exome sequencing and exome array CGH based on CNV spectrum in a large clinical cohort. *Genet Med*. 2015;17(8):623-629.
79. Sanford EF, Clark MM, Farnaes L, et al. Rapid whole genome sequencing has clinical utility in children in the PICU. *Pediatr Crit Care Med*. 2019;20(11):1007-1020.
80. Sparks TN, Lianoglou BR, Adami RR, et al. Exome sequencing for prenatal diagnosis in nonimmune hydrops fetalis. *N Engl J Med*. 2020;383(18):1746-1756.

81. Tatsumi K, Nishimura O, Itomi K, Tanegashima C, Kuraku S. Optimization and cost-saving in tagmentation-based mate-pair library preparation and sequencing. *Biotechniques*. 2015;58(5):253257.
82. UpToDate, Inc. Ataxia-telangiectasia. <https://www.uptodate.com>. Updated January 2023.
83. UpToDate, Inc. Autism spectrum disorder: evaluation and diagnosis. <https://www.uptodate.com>. Updated January 2023.
84. UpToDate, Inc. Autosomal dominant spinocerebellar ataxias. <https://www.uptodate.com>. Updated January 19, 2023.
85. UpToDate, Inc. Birth defects: approach to evaluation. <https://www.uptodate.com>. Updated January 2023.
86. UpToDate, Inc. Cervical dystonia: etiology, clinical features, and diagnosis. <https://www.uptodate.com>. Updated January 2023.
87. UpToDate, Inc. Congenital myopathies. <https://www.uptodate.com>. Updated January 2023.
88. UpToDate, Inc. Differential diagnosis of peripheral nerve and muscle disease. <https://www.uptodate.com>. Updated January 2023.

89. UpToDate, Inc. Duchenne and Becker muscular dystrophy: clinical features and diagnosis. <https://www.uptodate.com>. Updated January 2023.
90. UpToDate, Inc. Emery-Dreifuss muscular dystrophy. <https://www.uptodate.com>. Updated January 2023.
91. UpToDate, Inc. Etiology, clinical features, and diagnostic evaluation of dystonia. <https://www.uptodate.com>. Updated January 2023.
92. UpToDate, Inc. Friedreich ataxia. <https://www.uptodate.com>. Updated January 31, 2023.
93. UpToDate, Inc. Genetic association and GWAS studies: principles and applications. <https://www.uptodate.com>. Updated January 2023.
94. UpToDate, Inc. Genetic testing. <https://www.uptodate.com>. Updated January 2023.
95. UpToDate, Inc. Genetic testing and management of individuals at risk of hereditary breast and ovarian cancer syndromes. <https://www.uptodate.com>. Updated January 19, 2023.
96. UpToDate, Inc. Genetic testing in patients with a suspected primary immunodeficiency or autoinflammatory syndrome. <https://www.uptodate.com>. Updated January 2023.
97. UpToDate, Inc. Genetics of Alzheimer disease. <https://www.uptodate.com>. Updated January 2023.
98. UpToDate, Inc. Genomic disorders: an overview. <https://www.uptodate.com>. Updated January 2023.
99. UpToDate, Inc. Hereditary spastic paraplegia. <https://www.uptodate.com>. Updated January 2023.
100. UpToDate, Inc. Intellectual disability in children: evaluation for a cause. <https://www.uptodate.com>. Updated January 10, 2023.
101. UpToDate, Inc. Laboratory evaluation of the immune system. <https://www.uptodate.com>. Updated February 2, 2023.
102. UpToDate, Inc. Limb-girdle muscular dystrophy. <https://www.uptodate.com>. Updated January 2023.
103. UpToDate, Inc. Microcephaly: a clinical genetics approach. <https://www.uptodate.com>. Updated January 9, 2023.
104. UpToDate, Inc. Next-generation DNA sequencing (NGS): principles and clinical applications. <https://www.uptodate.com>. Updated January 2023.

105. UpToDate, Inc. Nonimmune hydrops fetalis. <https://www.uptodate.com>. Updated January 2023.
106. UpToDate, Inc. Overview of cerebellar ataxia in adults. <https://www.uptodate.com>. Updated January 19, 2023.
107. UpToDate, Inc. Overview of infantile epilepsy syndromes. <https://www.uptodate.com>. Updated January 2023.
108. UpToDate, Inc. Preimplantation genetic testing. <https://www.uptodate.com>. Updated January 2023.
109. UpToDate, Inc. Prenatal diagnosis of chromosomal imbalance: chromosomal microarray. <https://www.uptodate.com>. Updated January 2023.
110. UpToDate, Inc. Prenatal genetic evaluation of the fetus with anomalies or soft markers. <https://www.uptodate.com>. Updated January 2023.
111. UpToDate, Inc. Secondary findings from genetic testing. <https://www.uptodate.com>. Updated January 2023.
112. UpToDate, Inc. Seizures and epilepsy in children: clinical and laboratory diagnosis. <https://www.uptodate.com>. Updated January 2023.
113. UpToDate, Inc. Stillbirth: maternal and fetal evaluation. <https://www.uptodate.com>. Updated January 2023.
114. UpToDate, Inc. Tissue-agnostic cancer therapy: DNA mismatch repair deficiency, tumor mutational burden, and response to immune checkpoint blockade in solid tumors. <https://www.uptodate.com>. Updated January 3, 2023.
115. UpToDate, Inc. Tools for genetics and genomics: cytogenetics and molecular genetics. <https://www.uptodate.com>. Updated January 2023.
116. US Food & Drug Administration (FDA). 510(k) Substantial Equivalence Determination Decision Summary. NantHealth Next Generating Sequencing Tumor Profiling Test. <https://www.fda.gov>. Published November 9, 2019.
117. US Food & Drug Administration (FDA). De Novo Approval Letter. Helix Laboratory Platform. <https://www.fda.gov>. Published December 23, 2020.
118. Yang Y, Muzny DM, Xia F, et al. Molecular findings among patients referred for clinical whole-exome sequencing. *JAMA*. 2014;312(18):1870-1879.

119. Zhao C, Chai H, Zhou Q, et al. Exome sequencing analysis on products of conception: a cohort study to evaluate clinical utility and genetic etiology for pregnancy loss. *Genet Med*. 2021;23(3):435-442.
120. Zhou C, Chen S, Xu F, et al. Estimating tumor mutational burden across multiple cancer types using whole-exome sequencing. *Ann Transl Med*. 2021;9(18):1437.

Change Summary

07/01/2024 Provider Claims Codes Update, No Coverage Change.